A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

NCT06720987 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

140

Enrollment

INDUSTRY

Sponsor class

Conditions

KRAS G12C Mutation
KRAS G12S Mutation
Solid Tumor Malignancies
CRC (Colorectal Cancer)

Interventions

DRUG: KQB365
DRUG: Cetuximab
DRUG: KQB198

Sponsor

Kumquat Biosciences Inc.